Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignanciesRead more
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018Read more
New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21Read more
Quarterly report presentations
Medivir Corporate Governance documention.
Documentation from Medivir's Annual General Meetings.